Suppr超能文献

凝血酶及凝血酶受体激活肽在豚鼠体内的支气管收缩作用

Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo.

作者信息

Cicala C, Bucci M, De Dominicis G, Harriot P, Sorrentino L, Cirino G

机构信息

Dipartimento di Farmacologia Sperimentale, Universitá degli Studi di Napoli Federico II, Italy.

出版信息

Br J Pharmacol. 1999 Jan;126(2):478-84. doi: 10.1038/sj.bjp.0702303.

Abstract
  1. Several thrombin cellular effects are dependent upon stimulation of proteinase activated receptor-1 (PAR-1) localized over the cellular surface. Following activation by thrombin, a new N-terminus peptide is unmasked on PAR-1 receptor, which functions as a tethered ligand for the receptor itself. Synthetic peptides called thrombin receptor activating peptides (TRAPs), corresponding to the N-terminus residue unmasked, reproduce several thrombin cellular effects, but are devoid of catalytic activity. We have evaluated the bronchial response to intravenous administration of human alpha-thrombin or a thrombin receptor activating peptide (TRAP-9) in anaesthetized, artificially ventilated guinea-pigs. 2. Intravenous injection of thrombin (100 microkg(-1)) caused bronchoconstriction that was recapitulated by injection of TRAP-9 (1 mg kg(-1)). Animal pretreatment with the thrombin inhibitor Hirulog (10 mg kg(-1) i.v.) prevented thrombin-induced bronchoconstriction, but did not affect bronchoconstriction induced by TRAP-9. Both agents did not induce bronchoconstriction when injected intravenously to rats. 3. The bronchoconstrictor effect of thrombin and TRAP-9 was subjected to tolerance; however, in animals desensitized to thrombin effect, TRAP-9 was still capable of inducing bronchoconstriction, but not vice versa. 4. Depleting animals of circulating platelets prevented bronchoconstriction induced by both thrombin and TRAP-9. 5. Bronchoconstriction was paralleled by a biphasic change in arterial blood pressure, characterized by a hypotensive phase followed by a hypertensive phase. Thrombin-induced hypotension was not subject to tolerance and was inhibited by Hirulog; conversely, hypertension was subject to tolerance and was not inhibited by Hirulog. Hypotension and hypertension induced by TRAP-9 were neither subject to tolerance nor inhibited by Hirulog. 6. Our results indicate that thrombin causes bronchoconstriction in guinea-pigs through a mechanism that requires proteolytic activation of its receptor and the exposure of the tethered ligand peptide. Platelet activation might be triggered by the thrombin effect.
摘要
  1. 凝血酶的几种细胞效应依赖于对位于细胞表面的蛋白酶激活受体-1(PAR-1)的刺激。凝血酶激活后,PAR-1受体上会暴露出一个新的N端肽段,它作为受体自身的拴系配体发挥作用。称为凝血酶受体激活肽(TRAPs)的合成肽,与暴露出的N端残基相对应,可重现凝血酶的几种细胞效应,但没有催化活性。我们评估了在麻醉、人工通气的豚鼠中静脉注射人α-凝血酶或凝血酶受体激活肽(TRAP-9)后的支气管反应。2. 静脉注射凝血酶(100微克/千克)引起支气管收缩,注射TRAP-9(1毫克/千克)可重现该效应。用凝血酶抑制剂水蛭素(10毫克/千克静脉注射)预处理动物可预防凝血酶诱导的支气管收缩,但不影响TRAP-9诱导的支气管收缩。将这两种药物静脉注射给大鼠时均未诱导支气管收缩。3. 凝血酶和TRAP-9的支气管收缩作用会产生耐受性;然而,在对凝血酶作用脱敏的动物中,TRAP-9仍能诱导支气管收缩,但反之则不然。4. 使动物循环血小板耗竭可预防凝血酶和TRAP-9诱导的支气管收缩。5. 支气管收缩与动脉血压的双相变化平行,其特征是先出现低血压期,随后是高血压期。凝血酶诱导的低血压不产生耐受性,且受水蛭素抑制;相反,高血压产生耐受性,不受水蛭素抑制。TRAP-9诱导的低血压和高血压既不产生耐受性,也不受水蛭素抑制。6. 我们的结果表明,凝血酶通过一种需要其受体蛋白水解激活和拴系配体肽暴露的机制在豚鼠中引起支气管收缩。血小板激活可能由凝血酶的作用触发。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验